Clinical trials: Anticoagulation With Direct Oral Anticoagulants
Cerebral Venous Thrombosis, Anticoagulants and Thrombotic Disorders
Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients
The goal of this observational study is to learn the safety and efficacy of edoxaban and rivaroxaban in Chinese population with the age range from 18 to 80 years who take edoxaban or rivaroxaban to treat their cerebral venous…
- Conditions
- Cerebral Venous Thrombosis, Anticoagulants and Thrombotic Disorders, Anticoagulation Treatment, Anticoagulant Therapy
- Trial name
- NCT06947707
- Where
- China
- Volunteers
- 1,486 people
- Sponsor
- Xuanwu Hospital, Beijing
Anticoagulation With Direct Oral Anticoagulants
Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants 2
The investigators study aims to test the correlation between the Hemochron Signature point-of-care testing (POCT) device (ITC, USA) and low plasma levels of all three currently approved direct oral anticoagulants (DOAC…
- Trial name
- POCT-DOAC 2 (NCT02371070)
- Volunteers
- 60 people
- Sponsor
- University Hospital Tuebingen
Cancer, Atrial Fibrillation
Management of Atrial Fibrillation in Patients With Cancer (MAFIC Study)
The primary objective is to assess the safety and efficacy of switching from direct oral anticoagulants to low molecular weight heparin in cancer patients during antineoplastic therapy
- Trial name
- MAFIC (NCT04508855)
- Testing
- Low molecular weight heparin
- Where
- 2 sites in Greece
- Sponsor
- AHEPA University Hospital
Atrial Fibrillations, Heart Valve Prostheses
What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.
The optimal antithrombotic therapy for patients with atrial fibrillation (AF) with a CHA2DS2-VASc score ≥1 with concomitant acute coronary syndrome (ACS) or revascularisation by percutaneous coronary intervention (PCI) with…
- Conditions
- Atrial Fibrillations, Heart Valve Prostheses, Acute Coronary Syndromes, Coronary Artery Diseases
- Trial name
- WOEST 2 (NCT02635230)
- Testing
- Combination of chronic oral anticoagulation and a P2Y12 inhibitor with or without aspirin.
- Where
- 9 sites in Belgium, Netherlands
- Volunteers
- 2,200 people
- Sponsor
- R&D Cardiologie
Intracardiac Thrombus, STEMI
Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus
Left ventricular thrombus is found in 10 to 25% of patients with impaired left ventricular function following ST-segment elevation myocardial infarction and up to 20% in dilated cardiomyopathy in observational studies.
- Conditions
- Intracardiac Thrombus, STEMI, Heart Failure
- Trial name
- ARGONAUT (NCT05825573)
- Testing
- Vitamin K antagonist, Direct oral anticoagulant
- Where
- 35 sites in France, Reunion
- Volunteers
- 340 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Stroke
Urin-based Point-of-Care Testing for Direct Oral Anticoagulants in Stroke Patients
The goal of this study is to test a urine-based point-of-care testing device for direct oral anticoagulants in patients with stroke.
- Trial name
- UPTURN (NCT06037200)
- Testing
- Urin-based test by the DOASENSE Dipstick Device
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- University of Giessen
Bleeding
A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)
The purpose of this study was to evaluate the hemostatic efficacy of andexanet alfa (andexanet) in participants receiving a factor Xa (FXa) inhibitor (apixaban, rivaroxaban, edoxaban, enoxaparin) who were experiencing an acute…
- Trial name
- NCT02329327
- Testing
- Andexanet
- Where
- 87 sites in United States, Belgium and 7 more
- Volunteers
- 479 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Deep Vein Thrombosis, Pulmonary Embolism
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)
No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-VTE study is a nationwide cluster randomized cross-over study comparing efficacy and safety of…
- Trial name
- DANNOAC-VTE (NCT03129555)
- Testing
- Dabigatran Etexilate Oral Capsule, Rivaroxaban Oral Tablet, Edoxaban Oral Tablet
- Where
- 26 sites in Denmark
- Volunteers
- 5,000 people
- Sponsor
- Herlev and Gentofte Hospital
Anticoagulation
Accessibility to New Drugs Versus SOC in Sweden
The healthcare system in Sweden is publicly funded and aims to provide equal access to care irrespective of socioeconomic status. This includes ensuring equity in drug treatment.
- Trial name
- NCT03684395
- Testing
- DOACs: Rivaroxaban, Dabigatran, Apixaban, Standard of care (Warfarin)
- Where
- Sweden
- Volunteers
- 68,056 people
- Sponsor
- Bayer
Ischemic Stroke
Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants
DO-IT is an international, prospective observational registry evaluating whether the administration of intravenous thrombolysis (IVT) is safe and improves functional outcome in ischemic stroke patients with recent direct oral…
- Trial name
- DO-IT Cohort (NCT06556446)
- Testing
- Tenecteplase and Alteplase
- Where
- 33 sites in Austria, Belgium and 13 more
- Volunteers
- 2,800 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Endstage Renal Disease, Direct Oral Anticoagulants (DOACs)
Effect of Apiban Therapy on AVF Maturation in ESRD Patients
End-stage renal disease (ESRD) is a growing global health burden, and the creation of a native arteriovenous fistula (AVF) is the gold standard for vascular access in patients requiring hemodialysis [1].
- Conditions
- Endstage Renal Disease, Direct Oral Anticoagulants (DOACs), Arteriovenous Fistula, Arteriovenous Fistula Occlusion
- Trial name
- NCT07559942
- Testing
- Apixaban
- Where
- Pakistan
- Volunteers
- 190 people
- Sponsor
- Combined military hospital lahore
Pediatric Venous Thromboembolism
Rivaroxaban in Pediatric Patients With DVT
Prospective interventional randomized controlled trial to assess safety and efficacy of rivaroxaban in pediatric patients with acute deep venous thrombosis.
- Trial name
- NCT07618988
- Testing
- Rivaroxaban, Enoxaparin, Heparin
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Atrial Fibrillation, Atrial Flutter
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation
No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-AF study is a nationwide cluster randomized cross-over study comparing efficacy and safety of…
- Trial name
- DANNOAC-AF (NCT03129490)
- Testing
- Dabigatran Etexilate Oral Capsule, Rivaroxaban Oral Tablet, Edoxaban Oral Tablet
- Where
- 38 sites in Denmark
- Volunteers
- 11,000 people
- Sponsor
- Herlev and Gentofte Hospital
Atrial Fibrillation
A Real-World Comparison of Safety and Effectiveness of Novel Oral Anti-Coagulant (NOAC) Naïve and Warfarin Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage
The primary purpose of this study is to evaluate the risk of major bleeding and stroke/systemic embolism (SE) among novel oral anti-coagulant (OAC) naïve and warfarin naïve Medicare Advantage patients with non-valvular atrial…
- Trial name
- NCT03189069
- Testing
- Apixaban, Dabigatran, Rivaroxaban
- Volunteers
- 36,000 people
- Sponsor
- Bristol-Myers Squibb
Percutaneous Coronary Intervention (PCI), Atrial Fibrillation (AF)
Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation
Patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation require treatment with different antithrombotic drugs.
- Conditions
- Percutaneous Coronary Intervention (PCI), Atrial Fibrillation (AF), Oral Anticoagulation, P2Y12 Inhibitor
- Trial name
- MATRIX-2 (NCT05955365)
- Testing
- P2Y12 inhibitor, Aspirin, DOAC
- Where
- 15 sites in Belgium, France and 7 more
- Volunteers
- 3,010 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Chronic Subdural Hematoma, Atrial Fibrillation (AF)
Restarting Early Versus Later Anticoagulation for Chronic Subdural Hematoma With Atrial Fibrillation
The goal of this randomized clinical trial is to assess the benefit of early resumption versus late resumption of oral anticoagulation medication in adults with atrial fibrillation undergoing surgery for chronic subdural…
- Trial name
- RELACS (NCT06696079)
- Testing
- Early Resumption of Oral Anticoagulation Therapy, Late Resumption of Oral Anticoagulation Therapy
- Where
- 6 sites in Finland, Sweden
- Volunteers
- 332 people
- Sponsor
- Rahul Raj
Anticoagulation With Direct Oral Anticoagulants
Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants Extended
The investigators' study aims to test the correlation between CoaguChek point-of-care aPTT testing (Roche, Switzerland) and low plasma levels of all four currently EMA approved direct oral anticoagulants (DOAC; apixaban…
- Trial name
- POCT-DOAC ext (NCT04679298)
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- University Hospital Tuebingen
Ischemic Stroke
Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake
DO-IT is an international, multicenter, prospective, two-arm, randomized, open label, blinded endpoint superiority trial determining the safety and efficacy of intravenous thrombolysis (IVT) in participants experiencing an acute…
- Trial name
- DO-IT (NCT06571149)
- Testing
- Tenecteplase or Alteplase
- Where
- 109 sites in Austria, Belgium and 10 more
- Volunteers
- 906 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Anticoagulation With Direct Oral Anticoagulants
Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants 1
The investigators study aims to test the correlation between the CoaguChek point-of-care testing (POCT) device (Roche, Switzerland) and low plasma levels of all three currently approved direct oral anticoagulants (DOAC…
- Trial name
- POCT-DOAC 1 (NCT02371044)
- Volunteers
- 60 people
- Sponsor
- University Hospital Tuebingen
Medication Adherence, Atrial Fibrillation (AF)
SNAP AF-52: Dose Appropriateness and Adherence to Oral Anticoagulation in Adults ≥65 With Atrial Fibrillation in Primary Care (Ordu, Türkiye)
SNAP AF-52 is an ambidirectional observational registry conducted in family health centers (primary care) across Ordu, Türkiye, enrolling adults ≥65 years with a pre-existing diagnosis of atrial fibrillation.
- Conditions
- Medication Adherence, Atrial Fibrillation (AF), Direct Oral Anticoagulants (DOACs)
- Trial name
- SNAP AF-52 (NCT07242326)
- Where
- Turkey (Türkiye)
- Volunteers
- 1,000 people
- Sponsor
- Kotyora Family Medicine Health Management and Education Association